Back to Journals » ClinicoEconomics and Outcomes Research » Volume 4

Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection

Authors Thorlund K, Druyts E, El Khoury, Mills E

Received 21 August 2012

Accepted for publication 24 September 2012

Published 16 November 2012 Volume 2012:4 Pages 349—359

DOI https://doi.org/10.2147/CEOR.S37205

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Kristian Thorlund,1 Eric Druyts,2 Antoine C El Khoury,3 Edward J Mills2

1Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, 2Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada; 3Merck Sharp and Dohme, Whitehouse Station, NJ, USA

Background: Boceprevir and telaprevir have recently showed dramatically better treatment outcomes than conventional PEGylated interferon plus ribavirin for the treatment of hepatitis C virus genotype 1, but the average cost per patient is unknown.
Methods: In the UK context, we performed a budget impact analysis to estimate the average per patient cost of adding boceprevir or telaprevir to PEGylated interferon plus ribavirin therapy. We considered both standard-duration therapy and response-guided therapy regimens of boceprevir and telaprevir for treatment-naïve and treatment-experienced patients. Our model utilized monthly discontinuation rates. We built a Bayesian Markov model to account for uncertainty associated with the clinical input and cost data.
Results: The total average cost of response-guided therapy with boceprevir is £22,850 and £25,060 for treatment-naïve and treatment-experienced patients, respectively. By comparison, the total average cost of response-guided therapy with telaprevir was £29,930 and £31,880 for treatment-naïve and treatment-experienced patients, respectively, whereas the total average cost of standard-duration boceprevir is £34,680 and £34,350 and for telaprevir was £32,530 and £31,680 for treatment-naïve and treatment experienced patients, respectively.
Conclusion: Our results demonstrate that response-guided therapy with boceprevir is notably less costly than response-guided therapy with telaprevir. Our results also suggest that the standard treatment duration of boceprevir is slightly more costly than the standard treatment duration of telaprevir.

Keywords: hepatitis C, budget impact analysis, boceprevir, telaprevir

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Increased mortality among HIV-positive men on antiretroviral therapy: survival differences between sexes explained by late initiation in Uganda

Kanters S, Nansubuga M, Mwehire D, Odiit M, Kasirye M, Musoke W, Druyts E, Yaya S, Funk A, Ford N, Mills EJ

HIV/AIDS - Research and Palliative Care 2013, 5:111-119

Published Date: 29 May 2013

Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis

Thorlund K, Druyts E, Aviña-Zubieta JA, Mills EJ

Biologics: Targets and Therapy 2012, 6:417-427

Published Date: 3 December 2012

Predictive value of CD4 cell count nadir on long-term mortality in HIV-positive patients in Uganda

Bray S, Gedeon J, Hadi A, Kotb A, Rahman T, Sarwar E, Savelyeva A, Sévigny M, Bakanda C, Birungi J, Chan K, Yaya S, Deonandan R, Mills EJ

HIV/AIDS - Research and Palliative Care 2012, 4:135-140

Published Date: 17 August 2012

Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis

Cooper CL, Druyts E, Thorlund K, Nachega JB, El Khoury AC, O'Regan C, Mills EJ

Therapeutics and Clinical Risk Management 2012, 8:105-130

Published Date: 9 March 2012

Multiple treatment comparison meta-analyses: a step forward into complexity

Mills E, Bansback N, Ghement I, Thorlund K, Kelly S, Puhan M, Wright J

Clinical Epidemiology 2011, 3:193-202

Published Date: 27 May 2011

Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis

Mills EJ, Druyts E, Ghement I, Puhan MA

Clinical Epidemiology 2011, 3:107-129

Published Date: 28 March 2011

Tuberculosis mortality in HIV-infected individuals: a cross-national systematic assessment

Christopher Au-Yeung, Steve Kanters, Erin Ding, et al

Clinical Epidemiology 2011, 3:21-29

Published Date: 19 January 2011

Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis

Oghenowede Eyawo, Jean Nachega, Pierre Lefebvre, et al

Clinical Ophthalmology 2009, 3:447-456

Published Date: 31 July 2009

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010